Profound Medical Corp. reported a significant increase in revenue for the fiscal year ending December 31, 2025, achieving $16.1 million, a 51% rise from $10.7 million in 2024. This growth was driven by higher sales of both capital equipment and recurring non-capital revenue, with the latter contributing $9.7 million, up from $8.2 million the previous year. Despite this revenue growth, the company recorded a net loss of $42.6 million, compared to a loss of $27.8 million in 2024, reflecting increased operating expenses primarily in research and development (R&D) and selling, general, and administrative (SG&A) costs.
Operating expenses rose to $52.6 million, a 31% increase from $40.1 million in 2024. R&D expenses accounted for $20.6 million, up 21% year-over-year, driven by increased clinical trial activities, particularly for the CAPTAIN trial. SG&A expenses surged by 39% to $32.1 million, attributed to an expanded sales force and increased marketing efforts. The gross profit margin improved to 71% in 2025, up from 66% in 2024, indicating better pricing and sales performance.
In terms of strategic developments, Profound Medical has been actively pursuing commercialization of its TULSA-PRO system, which utilizes AI-powered, MRI-guided technology for incision-free tissue ablation. The company has also been expanding its market presence, with approximately 76% of revenues generated in the United States, 5% in the European Union, and 19% in Asia. The company’s workforce has grown to 162 employees, reflecting its commitment to scaling operations and enhancing product adoption.
Looking ahead, Profound Medical anticipates continued growth driven by the commercialization of its products and potential new market opportunities. The company has raised capital through public offerings and private placements, generating net proceeds of approximately $40.8 million in December 2025, which will be used to support ongoing commercialization efforts and product development. However, the company also acknowledges the need for additional financing to sustain its operations and expand its market reach, particularly as it navigates the complexities of regulatory approvals and market acceptance.
About Profound Medical Corp.
Profound Medical develops MRI-guided, incision-free therapeutic systems for minimally invasive ablation of diseased tissue, primarily targeting prostate conditions and uterine fibroids. Its flagship products, TULSA-PRO and Sonalleve, utilize real-time MRI, focused ultrasound, and thermal feedback to deliver precise, customizable treatments. Serving global markets, the company offers solutions that aim to improve clinical outcomes, reduce side effects, and enable outpatient procedures in urology and gynecology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.